Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis.

Author: AryalMadan Raj, DhakalBinod, GiriSmith, GrimshawAlyssa, HuntingtonScott P, PathakRanjan, YuHan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Daratumumab, Bortezomib, Melphalan, and Prednisone (SUCRA 0.960) were the most effective treatment regimen for newly diagnosed transplant-ineligible multiple myeloma (tiMM) patients. Daratumumab, lenalidomide, and dexamethasone (Dara_RD, SUCRA 0.847) were the second most effective and also had the most favorable toxicity profile.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: Several treatment options are available for the management of older adults with newly diagnosed patients with Multiple Myeloma (MM) who are ineligible for hematopoietic cell transplantation (tiMM). We aimed to identify treatment options that provide the best balance in terms of efficac...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/32513568

データ提供：米国国立医学図書館（NLM）

Multiple Myeloma Treatment: Balancing Efficacy and Safety

This study explores the [treatment options] for [transplant-ineligible patients] with [newly diagnosed multiple myeloma]. The researchers conducted a [systematic review and meta-analysis] to identify the most effective and safest regimens for this patient population.

Imagine a camel caravan facing a challenging journey through the desert (multiple myeloma). Each camel (patient) has unique needs, and the caravan leader (healthcare professional) must choose the best path (treatment regimen) to ensure the safety and well-being of the entire group. This study investigates the most effective and safest routes for those camels who cannot undergo a major transformation (transplant).

Efficacy and Safety: A Balancing Act

The study found that [Daratumumab, Bortezomib, Melphalan and Prednisone] was the most effective regimen for [PFS]. However, the study also highlighted the importance of considering the [toxicity profile] of different treatment options.

Navigating the Desert of Multiple Myeloma Treatment

This research offers valuable insights into the complex world of [multiple myeloma treatment]. It emphasizes the need for [individualized care] and a [holistic approach] that balances [efficacy] and [safety]. Just as a wise camel guide chooses a path that minimizes risk while maximizing the group's chances of success, healthcare professionals must carefully consider the individual needs of their patients when making treatment decisions.

Dr.Camel's Conclusion

This study highlights the challenges and rewards of [multiple myeloma treatment], emphasizing the importance of balancing efficacy and safety in choosing the right regimen for each patient. It's a reminder that the journey through this complex disease requires a skilled guide (healthcare professional) who understands the individual needs of their patients. By carefully considering the options and seeking the most effective and safest path, we can help patients navigate the desert of multiple myeloma with greater strength and hope.

Date :
  1. Date Completed 2021-07-28
  2. Date Revised 2022-01-04
Further Info :

Pubmed ID

32513568

DOI: Digital Object Identifier

NIHMS1765544

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.